Trevi Therapeutics (TRVI) Competitors $7.27 +0.01 (+0.14%) Closing price 04:00 PM EasternExtended Trading$7.18 -0.09 (-1.31%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRVI vs. MIRM, MLTX, PTGX, APLS, MENS, MTSR, SRRK, KYMR, AMRX, and XENEShould you be buying Trevi Therapeutics stock or one of its competitors? The main competitors of Trevi Therapeutics include Mirum Pharmaceuticals (MIRM), MoonLake Immunotherapeutics (MLTX), Protagonist Therapeutics (PTGX), Apellis Pharmaceuticals (APLS), Jyong Biotech (MENS), Metsera (MTSR), Scholar Rock (SRRK), Kymera Therapeutics (KYMR), AMNEAL PHARMACEUTICALS (AMRX), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry. Trevi Therapeutics vs. Its Competitors Mirum Pharmaceuticals MoonLake Immunotherapeutics Protagonist Therapeutics Apellis Pharmaceuticals Jyong Biotech Metsera Scholar Rock Kymera Therapeutics AMNEAL PHARMACEUTICALS Xenon Pharmaceuticals Trevi Therapeutics (NASDAQ:TRVI) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation. Which has more volatility & risk, TRVI or MIRM? Trevi Therapeutics has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500. Which has stronger earnings & valuation, TRVI or MIRM? Trevi Therapeutics has higher earnings, but lower revenue than Mirum Pharmaceuticals. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrevi TherapeuticsN/AN/A-$47.91M-$0.42-17.31Mirum Pharmaceuticals$336.89M11.09-$87.94M-$1.21-61.44 Do analysts prefer TRVI or MIRM? Trevi Therapeutics currently has a consensus target price of $20.11, suggesting a potential upside of 176.63%. Mirum Pharmaceuticals has a consensus target price of $74.13, suggesting a potential downside of 0.29%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Trevi Therapeutics is more favorable than Mirum Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trevi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.20Mirum Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Is TRVI or MIRM more profitable? Trevi Therapeutics has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -13.65%. Mirum Pharmaceuticals' return on equity of -24.76% beat Trevi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Trevi TherapeuticsN/A -41.44% -38.21% Mirum Pharmaceuticals -13.65%-24.76%-8.50% Does the media favor TRVI or MIRM? In the previous week, Mirum Pharmaceuticals had 4 more articles in the media than Trevi Therapeutics. MarketBeat recorded 13 mentions for Mirum Pharmaceuticals and 9 mentions for Trevi Therapeutics. Mirum Pharmaceuticals' average media sentiment score of 1.31 beat Trevi Therapeutics' score of 1.26 indicating that Mirum Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirum Pharmaceuticals 10 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in TRVI or MIRM? 95.8% of Trevi Therapeutics shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by company insiders. Comparatively, 22.9% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryTrevi Therapeutics beats Mirum Pharmaceuticals on 9 of the 16 factors compared between the two stocks. Get Trevi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRVI vs. The Competition Export to ExcelMetricTrevi TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$885.34M$3.10B$5.69B$9.68BDividend YieldN/A2.28%6.66%4.54%P/E Ratio-17.3120.9982.6526.40Price / SalesN/A360.50498.44197.40Price / CashN/A43.5325.7028.92Price / Book5.599.8811.246.06Net Income-$47.91M-$53.38M$3.28B$266.05M7 Day Performance-2.02%-0.14%0.15%-0.07%1 Month Performance-0.82%9.18%8.34%5.83%1 Year Performance130.06%7.53%54.21%17.88% Trevi Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRVITrevi Therapeutics2.5643 of 5 stars$7.27+0.1%$20.11+176.6%+129.7%$885.34MN/A-17.3120News CoveragePositive NewsMIRMMirum Pharmaceuticals3.4681 of 5 stars$71.81+0.4%$74.13+3.2%+71.4%$3.59B$336.89M-59.35140Positive NewsMLTXMoonLake Immunotherapeutics2.3586 of 5 stars$54.63-2.3%$74.43+36.2%+19.1%$3.59BN/A-19.652News CoveragePositive NewsPTGXProtagonist Therapeutics1.6806 of 5 stars$56.88-1.0%$67.20+18.1%+37.7%$3.58B$434.43M81.26120News CoveragePositive NewsAPLSApellis Pharmaceuticals4.2044 of 5 stars$27.52-1.6%$34.12+24.0%-29.1%$3.53B$781.37M-15.12770News CoveragePositive NewsMENSJyong BiotechN/A$47.00+2.2%N/AN/A$3.50BN/A0.0031Positive NewsGap UpMTSRMetseraN/A$32.59-1.4%$55.00+68.8%N/A$3.47BN/A0.0081News CoveragePositive NewsAnalyst UpgradeSRRKScholar Rock4.4972 of 5 stars$33.33-6.1%$45.75+37.3%+251.1%$3.41B$33.19M-11.45140News CoveragePositive NewsKYMRKymera Therapeutics3.4172 of 5 stars$41.82-5.2%$59.11+41.3%-14.8%$3.15B$47.07M-12.05170Positive NewsAMRXAMNEAL PHARMACEUTICALS2.7801 of 5 stars$9.28-3.2%$11.60+25.0%+10.4%$3.01B$2.79B928.938,100Positive NewsXENEXenon Pharmaceuticals2.6033 of 5 stars$38.14-1.8%$53.20+39.5%-4.0%$2.99B$9.43M-10.74210News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies MIRM Alternatives MLTX Alternatives PTGX Alternatives APLS Alternatives MENS Alternatives MTSR Alternatives SRRK Alternatives KYMR Alternatives AMRX Alternatives XENE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRVI) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredOne tiny company just cracked Google’s $19B problemGoogle’s AI-powered search could cost $20 billion a year in electricity—nearly half its profits. But new resea...True Market Insiders | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trevi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TRVI Stock Alerts